Zobrazeno 1 - 10
of 1 960
pro vyhledávání: '"Poly(ADP-ribose) Polymerase Inhibitor"'
Autor:
Renming Huang, Feng Ji, Leyi Huang, Yueying Qin, Zhiyu Liang, Miaoyan Huang, Chunyan Li, Jian Ban
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThis meta-analysis was performed to evaluate the efficacy and safety of angiogenesis inhibitors (Ais) combined with poly ADP ribose polymerase inhibitors (PARPi) in the maintenance treatment of advanced ovarian cancer (OC).Materials and m
Externí odkaz:
https://doaj.org/article/1be85c1c3e3f42b8841fe253b0dc22c0
Publikováno v:
Cells, Vol 13, Iss 22, p 1847 (2024)
Poly (ADP-ribose) polymerase inhibitors (PARPis) show cytotoxicity in homologous recombination deficiency (HRD) seen in BRCA-mutant ovarian cancer (OvCa). Despite initial responses, resistance often develops. The reintroduction of different PARPis, s
Externí odkaz:
https://doaj.org/article/62efb17e881540499b63f49099b8d779
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10311-10324 (2023)
Preclinical and clinical studies have suggested potential synergies of combining poly (ADP-ribose) polymerase (PARP) inhibitors and novel hormonal therapies (NHT) for patients with metastatic castration-resistant prostate cancer (mCRPC). We systemati
Externí odkaz:
https://doaj.org/article/4e06a29a46b84d40bd74b6c214cad917
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1301-1309 (2023)
Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that i
Externí odkaz:
https://doaj.org/article/daec0b61338044bbb23da71553b951f5
Autor:
Wenbin Li, Lin Gao, Xin Yi, Shuangfeng Shi, Jie Huang, Leming Shi, Xiaoyan Zhou, Lingying Wu, Jianming Ying
Publikováno v:
Genomics, Proteomics & Bioinformatics, Vol 21, Iss 5, Pp 962-975 (2023)
Defects in genes involved in the DNA damage response cause homologous recombination repair deficiency (HRD). HRD is found in a subgroup of cancer patients for several tumor types, and it has a clinical relevance to cancer prevention and therapies. Ac
Externí odkaz:
https://doaj.org/article/b7c25fd985ea486b8e413214da343df5
Autor:
Nam Kyeong Kim, Yeorae Kim, Hee Seung Kim, Soo Jin Park, Dong Won Hwang, Sung Jong Lee, Ji Geun Yoo, Suk‐Joon Chang, Joo‐Hyuk Son, Tae‐Wook Kong, Jeeyeon Kim, Seung‐Hyuk Shim, A Jin Lee, Dong Hoon Suh, Yoo‐Young Lee
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19449-19459 (2023)
Abstract Objective To identify the risk factors for failure of first‐line poly (ADP‐ribose) polymerase inhibitor (PARPi) maintenance therapy in patients with advanced ovarian cancer. Method Patients with stage III‐IV epithelial ovarian cancer w
Externí odkaz:
https://doaj.org/article/21de0d1f7a8243f78d1bbff57b91bab3
Publikováno v:
Journal of Analytical Science and Technology, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors that are effective against ovarian and breast cancers with breast cancer susceptibility gene (BRCA) mutations have undesirable side effects, such as hematological toxicity. AZD5305, a selective
Externí odkaz:
https://doaj.org/article/e2e9e3d385bf4f43b57248604d35b16e
Autor:
Xiangyu Chen, Yang Pan, Qihua Wang, Congzhe Ren, Muwei Li, Xuexue Hao, Lijun Xie, Xiaoqiang Liu
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundStudies using novel antiandrogens (NAA) in patients with metastatic castration-resistant prostate cancer (mCRPC) have shown overall survival benefit. As patients develop resistance to NAA therapy, the poly(ADP-ribose) polymerase inhibitor (
Externí odkaz:
https://doaj.org/article/1f805f6929174a4facf0a849ae44a9f9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.